99 related articles for article (PubMed ID: 11484890)
1. Expression of CD30 ligand and CD30 receptor in normal thyroid and benign and malignant thyroid nodules.
Trovato M; Villari D; Ruggeri RM; Quattrocchi E; Fragetta F; Simone A; Scarfi R; Magro G; Batolo D; Trimarchi F; Benvenga S
Thyroid; 2001 Jul; 11(7):621-8. PubMed ID: 11484890
[TBL] [Abstract][Full Text] [Related]
2. Co-expression of interleukin-6 (IL-6) and interleukin-6 receptor (IL-6R) in thyroid nodules is associated with co-expression of CD30 ligand/CD30 receptor.
Ruggeri RM; Villari D; Simone A; Scarfi R; Attard M; Orlandi F; Barresi G; Trimarchi F; Trovato M; Benvenga S
J Endocrinol Invest; 2002 Dec; 25(11):959-66. PubMed ID: 12553555
[TBL] [Abstract][Full Text] [Related]
3. Expression of the hepatocyte growth factor and c-met in normal thyroid, non-neoplastic, and neoplastic nodules.
Trovato M; Villari D; Bartolone L; Spinella S; Simone A; Violi MA; Trimarchi F; Batolo D; Benvenga S
Thyroid; 1998 Feb; 8(2):125-31. PubMed ID: 9510120
[TBL] [Abstract][Full Text] [Related]
4. HGF/C-MET system pathways in benign and malignant histotypes of thyroid nodules: an immunohistochemical characterization.
Ruggeri RM; Vitarelli E; Barresi G; Trimarchi F; Benvenga S; Trovato M
Histol Histopathol; 2012 Jan; 27(1):113-21. PubMed ID: 22127603
[TBL] [Abstract][Full Text] [Related]
5. Expression and regulation of CD30 ligand and CD30 in human leukemia-lymphoma cell lines.
Gruss HJ; DaSilva N; Hu ZB; Uphoff CC; Goodwin RG; Drexler HG
Leukemia; 1994 Dec; 8(12):2083-94. PubMed ID: 7528856
[TBL] [Abstract][Full Text] [Related]
6. Distinctive expression of STAT3 in papillary thyroid carcinomas and a subset of follicular adenomas.
Trovato M; Grosso M; Vitarelli E; Ruggeri RM; Alesci S; Trimarchi F; Barresi G; Benvenga S
Histol Histopathol; 2003 Apr; 18(2):393-9. PubMed ID: 12647789
[TBL] [Abstract][Full Text] [Related]
7. Reverse signaling via CD30 ligand.
Wiley SR; Goodwin RG; Smith CA
J Immunol; 1996 Oct; 157(8):3635-9. PubMed ID: 8871664
[TBL] [Abstract][Full Text] [Related]
8. CD30 ligand expression in nonmalignant and Hodgkin's disease-involved lymphoid tissues.
Gruss HJ; Pinto A; Gloghini A; Wehnes E; Wright B; Boiani N; Aldinucci D; Gattei V; Zagonel V; Smith CA; Kadin ME; von Schilling C; Goodwin RG; Herrmann F; Carbone A
Am J Pathol; 1996 Aug; 149(2):469-81. PubMed ID: 8701986
[TBL] [Abstract][Full Text] [Related]
9. Characterization of the CD30L binding domain on the human CD30 molecule using anti-CD30 antibodies.
Franke AC; Jung D; Ellis TM
Hybridoma; 2000 Feb; 19(1):43-8. PubMed ID: 10768840
[TBL] [Abstract][Full Text] [Related]
10. CD30 ligand is frequently expressed in human hematopoietic malignancies of myeloid and lymphoid origin.
Gattei V; Degan M; Gloghini A; De Iuliis A; Improta S; Rossi FM; Aldinucci D; Perin V; Serraino D; Babare R; Zagonel V; Gruss HJ; Carbone A; Pinto A
Blood; 1997 Mar; 89(6):2048-59. PubMed ID: 9058727
[TBL] [Abstract][Full Text] [Related]
11. Targeting CD30/CD30L in oncology and autoimmune and inflammatory diseases.
Oflazoglu E; Grewal IS; Gerber H
Adv Exp Med Biol; 2009; 647():174-85. PubMed ID: 19760074
[TBL] [Abstract][Full Text] [Related]
12. Loss of heterozygosity of the long arm of chromosome 7 in follicular and anaplastic thyroid cancer, but not in papillary thyroid cancer.
Trovato M; Fraggetta F; Villari D; Batolo D; Mackey K; Trimarchi F; Benvenga S
J Clin Endocrinol Metab; 1999 Sep; 84(9):3235-40. PubMed ID: 10487693
[TBL] [Abstract][Full Text] [Related]
13. CD30 ligand in lymphoma patients with CD30+ tumors.
Younes A; Consoli U; Snell V; Clodi K; Kliche KO; Palmer JL; Gruss HJ; Armitage R; Thomas EK; Cabanillas F; Andreeff M
J Clin Oncol; 1997 Nov; 15(11):3355-62. PubMed ID: 9363866
[TBL] [Abstract][Full Text] [Related]
14. Immunoexpression of the CD30 ligand/CD30 and IL-6/IL-6R signals in thyroid autoimmune diseases.
Ruggeri RM; Barresi G; Sciacchitano S; Trimarchi F; Benvenga S; Trovato M
Histol Histopathol; 2006 Mar; 21(3):249-56. PubMed ID: 16372246
[TBL] [Abstract][Full Text] [Related]
15. Human angiogenin fused to human CD30 ligand (Ang-CD30L) exhibits specific cytotoxicity against CD30-positive lymphoma.
Huhn M; Sasse S; Tur MK; Matthey B; Schinköthe T; Rybak SM; Barth S; Engert A
Cancer Res; 2001 Dec; 61(24):8737-42. PubMed ID: 11751393
[TBL] [Abstract][Full Text] [Related]
16. CITED1 protein expression suggests Papillary Thyroid Carcinoma in high throughput tissue microarray-based study.
Prasad ML; Pellegata NS; Kloos RT; Barbacioru C; Huang Y; de la Chapelle A
Thyroid; 2004 Mar; 14(3):169-75. PubMed ID: 15072698
[TBL] [Abstract][Full Text] [Related]
17. Deciphering CD30 ligand biology and its role in humoral immunity.
Kennedy MK; Willis CR; Armitage RJ
Immunology; 2006 Jun; 118(2):143-52. PubMed ID: 16771849
[TBL] [Abstract][Full Text] [Related]
18. CD30 ligand/CD30 plays a critical role in Th17 differentiation in mice.
Sun X; Yamada H; Shibata K; Muta H; Tani K; Podack ER; Yoshikai Y
J Immunol; 2010 Aug; 185(4):2222-30. PubMed ID: 20639486
[TBL] [Abstract][Full Text] [Related]
19. A novel role for reciprocal CD30-CD30L signaling in the cross-talk between natural killer and dendritic cells.
Simhadri VL; Hansen HP; Simhadri VR; Reiners KS; Bessler M; Engert A; von Strandmann EP
Biol Chem; 2012 Jan; 393(1-2):101-6. PubMed ID: 22628304
[TBL] [Abstract][Full Text] [Related]
20. Proliferation of CD30+ T-helper 2 lymphoma cells can be inhibited by CD30 receptor cross-linking with recombinant CD30 ligand.
Willers J; Dummer R; Kempf W; Kündig T; Burg G; Kadin ME
Clin Cancer Res; 2003 Jul; 9(7):2744-54. PubMed ID: 12855655
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
